Pharmafile Logo
Pharmafocus logo
Advanced Search

Velcade

Showing 7 posts of 22 posts found.

Celgene image

Celgene predicts trio of blockbusters

June 5, 2013
Sales and Marketing Celgene, Pomalidomide, Revlamid, Velcade

Europe’s medicines committee the CHMP has just adopted a positive opinion for Celgene’s new multiple myeloma treatment Pomalidomide Celgene (pomalidomide). …

News

J&J cancer drugs get EU approval

October 2, 2012
Sales and Marketing Cancer, Dacogen, EU, J&J, JJ, Velcade

Two of Johnson & Johnson’s key cancer drugs have been shown the green light from the European Commission. Janssen-Cilag International’s …

News
Velcade image

Speedy approval for Onyx’ multiple myeloma drug

July 24, 2012
Research and Development, Sales and Marketing FDA, Janssen, Kyprolis, Onyx, Takeda, Velcade

Onyx’ Kyprolis has gained an accelerated approval by the FDA to treat patients with late-stage multiple myeloma.  Kyprolis (carfilzomib), a …

News
Janssen's Velcade (bortezomib)

NICE recommends thalidomide ahead of Velcade

July 27, 2011
Sales and Marketing NICE, Thalidomide, Velcade

NICE has recommended Celgene’s thalidomide ahead of J&J’s Velcade for multiple myeloma. Celgene’s drug is recommended in combination with an …

News

NICE backs Celgene’s thalidomide and Janssen’s Velcade

June 21, 2011
Sales and Marketing NICE, Thalidomide, Velcade, multiple myeloma

Celgene’s thalidomide and Janssen-Cilag’s Velcade have been given the thumbs up by NICE as a treatment for a cancer that …

News

J&J and Takeda issue recall for cancer drug Velcade

November 22, 2010
Manufacturing and Production J&J, JJ, Johnson & Johnson, Takeda Pharmaceuticals, Velcade, bortezomib, pharma manufacturing, product recalls

Johnson & Johnson has been affected by another product recall, on this occasion concerning the cancer drug Velcade (bortezomib) sold …

News
Velcade

Janssen to appeal against Velcade decision

August 26, 2010
Medical Communications, Sales and Marketing NICE, Thalidomide, Velcade, multiple myeloma

Celgene’s Thalidomide has been recommended by NICE for multiple myeloma ahead of Janssen-Cilag’s Velcade. A final appraisal determination says that …

News
The Gateway to Local Adoption Series

Latest content

Bramacare launches new AI platform to improve eating disorder care

March 31, 2026

Doccla appoints Jonathan Serjeant as Chief Medical Officer

March 31, 2026

SAH Diagnostics opens new diagnostics centre in Bristol

March 30, 2026

Abselion appoints Dale Gordon as Chair

March 30, 2026

Stage4You encourages stage 4 bowel cancer patients to prioritise mental health ahead of Bowel Cancer Awareness Month

March 26, 2026